TRIAL DETAIL

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Drug:
Trial Name:
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 10/01/2007
Age of Trial (yrs) 16.5
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
GDC4255g
Sponsor:
Genentech
Patient Contact:
See site contact info below
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This drug was initially developed by Piramed in the United Kingdom. GDC-0941 selectivity has not yet been published, so this information is unknown. We have been told informally that this oral drug inhibits multiple class I PI3K’s. It is currently in trial at Dana Farber in Boston, Mass. under George Demetri, MD.

Trial Links

 
 

Trial Results

 
 

Drug Information

The identification of GDC-0941
 
Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation
 

Trial Sites

Name
Address
City
State
Zip
Country
450 Brookline Ave
Boston
MA
02215-5450
USA
10460 N. 92nd Street, Suite 206
Scottsdale
AZ
85248
USA
4100 John R
Detroit
MI
48201
USA